A Small-Scale Clinical Trial to Determine the Safety and Efficacy of Testosterone Replacement Therapy in Hypogonadal Men with Spinal Cord Injury
A Small-Scale Clinical Trial to Determine the Safety and Efficacy of Testosterone Replacement Therapy in Hypogonadal Men with Spinal Cord Injury
复制标题
DOI：
10.1055/s-0031-1280797
复制
发表时间：
2011-07-01
影响因子：
2.2
通讯作者：
Spungen, A. M.
中科院分区：
文献类型：
--
作者：
Bauman, W. A.;Cirnigliaro, C. M.;Spungen, A. M.
患有脊髓损伤的男性患继发性疾病的风险增加，包括代谢紊乱、加速的肌肉骨骼萎缩，以及某些人的性腺功能减退症，这可能进一步对代谢和身体成分产生不利影响。进行了一项前瞻性、开放标签、对照药物干预试验，以确定12个月的睾酮替代治疗是否会增加患有脊髓损伤的性腺功能减退男性的瘦组织质量和静息能量消耗。健康的正常性腺（n = 11）和性腺功能减退（n = 11）慢性脊髓损伤的门诊患者入组。性腺功能减退的受试者每天接受经皮睾酮（5或10 mg），持续12个月。在基线和12个月时测量身体成分和静息能量消耗。睾酮替代治疗组增加了全身瘦组织质量（49.6 +/- 7.6 vs. 53.1 +/- 6.9 kg; p
Men with spinal cord injury are at an increased risk for secondary medical conditions, including metabolic disorders, accelerated musculoskeletal atrophy, and, for some, hypogonadism, a deficiency, which may further adversely affect metabolism and body composition. A prospective, open label, controlled drug intervention trial was performed to determine whether 12 months of testosterone replacement therapy increases lean tissue mass and resting energy expenditure in hypogonadal males with spinal cord injury. Healthy eugonadal (n = 11) and hypogonadal (n = 11) outpatients with chronic spinal cord injury were enrolled. Hypogonadal subjects received transdermal testosterone (5 or 10 mg) daily for 12 months. Measurements of body composition and resting energy expenditure were obtained at baseline and 12 months. The testosterone replacement therapy group increased lean tissue mass for total body (49.6 +/- 7.6 vs. 53.1 +/- 6.9 kg; p